Intravesicale onabotulinumtoxine-A-injecties bij therapieresistente kinderen met een niet-neurogene overactieve blaas

Abstract

Overactive bladder (OAB) with urinary incontinence poses a potentially significant impact on daily activities and quality of life. Due to its successful outcomes in the treatment of neurogenic bladder, intravesical botulinum‑A toxin (BTX-A) became a possible solution for children refractory to treatment. 50 children (41 boys) with a median age of 9.9 years were included. In the short term, there was a significant increase in FBV after initial BTX‑A treatment. In the short (< 6 months) and long term (6–12 months) 72 and 46% showed improvement of continence, respectively. Male gender and small baseline FBV predict a positive outcome on continence in the long term. In refractory OAB children, BTX‑A injections are safe and effective in enlarging bladder volume and reducing OAB symptoms, particularly in the first six months after injection.